Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK1 | P06493 | 6/20 | 0.63 |
| ▸ | MTOR | P42345 | 5/20 | 0.63 |
| ▸ | CDK2 | P24941 | 5/20 | 0.63 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.63 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.63 |
| ▸ | IKBKB | O14920 | 8/20 | 0.63 |
| ▸ | SMG1 | Q96Q15 | 4/20 | 0.54 |
| ▸ | KDR | P35968 | 2/20 | 0.54 |
| ▸ | GSK3B | P49841 | 2/20 | 0.53 |
| ▸ | DKK1 | O94907 | 1/20 | 0.53 |
| ▸ | JAK2 | O60674 | 4/20 | 0.52 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.52 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.52 |
| ▸ | JAK3 | P52333 | 2/20 | 0.52 |
| ▸ | NAMPT | P43490 | 1/20 | 0.51 |
| ▸ | CDC7 | O00311 | 1/20 | 0.51 |
| ▸ | PLK4 | O00444 | 1/20 | 0.51 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.51 |
| ▸ | AURKA | O14965 | 1/20 | 0.51 |
| ▸ | DCLK1 | O15075 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3518288 | 0.87 | IKBKB (0.82) | CDK1MTORCDK2PIK3CAPIK3CG | |
| SCHEMBL3015105 | 0.87 | CDK5 (0.60) | PIK3CAPIK3CGIKBKBGSK3BJAK2 | |
| SCHEMBL2938991 | 0.86 | JAK2 (0.56) | PIK3CAPIK3CGIKBKBGSK3BJAK2 | |
| SCHEMBL3521443 | 0.84 | IKBKB (0.81) | CDK1MTORCDK2PIK3CAPIK3CG | |
| SCHEMBL14348380 | 0.84 | KMT2A (0.52) | CDK1MTORCDK2PIK3CAPIK3CG | |
| SCHEMBL3518244 | 0.81 | IKBKB (0.85) | CDK1MTORCDK2PIK3CAPIK3CG | |
| SCHEMBL14348340 | 0.81 | MAPT (0.60) | PIK3CGGSK3BJAK2HDAC1HDAC6 | |
| SCHEMBL3516842 | 0.80 | IKBKB (0.65) | CDK1MTORCDK2PIK3CAPIK3CG | |
| SCHEMBL3524262 | 0.78 | IKBKB (1.00) | IKBKBGSK3BDKK1JAK2HDAC1 | |
| SCHEMBL3523274 | 0.78 | ABL1 (0.65) | CDK1MTORCDK2PIK3CAPIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2069314-A1 | PYRIMIDINES DERIVATIVES AND THEIR USE AS KINASE INHIBITORS | CGI Pharmaceuticals, Inc. (US) | 2009-06-17 | — | — | EP | claimed |
| US-20080125417-A1 | CERTAIN PYRIMIDINES, METHOD OF MAKING, AND METHOD OF USE THEREOF | CGI PHARMACEUTICALS, INC. | 2008-05-29 | — | — | US | claimed |
| WO-2008033834-A1 | PYRIMIDINES DERIVATIVES AND THEIR USE AS KINASE INHIBITORS | CGI PHARMACEUTICALS, INC. (US) | 2008-03-20 | — | — | WO | claimed |
| EP-2172460-A1 | Compositions useful as inhibitors of JAK and other protein kinases | Vertex Pharmaceuticals Incorporated (US) | 2010-04-07 | — | — | EP | disclosed |
| EP-1562911-B1 | COMPOSITIONS USEFUL AS INHIBITORS OF JAK AND OTHER PROTEIN KINASES | VERTEX PHARMA (US) | 2010-01-06 | — | — | EP | disclosed |
| EP-2069314-A1 | PYRIMIDINES DERIVATIVES AND THEIR USE AS KINASE INHIBITORS | CGI Pharmaceuticals, Inc. (US) | 2009-06-17 | — | — | EP | disclosed |
| US-20080125417-A1 | CERTAIN PYRIMIDINES, METHOD OF MAKING, AND METHOD OF USE THEREOF | CGI PHARMACEUTICALS, INC. | 2008-05-29 | — | — | US | disclosed |
| WO-2008033834-A1 | PYRIMIDINES DERIVATIVES AND THEIR USE AS KINASE INHIBITORS | CGI PHARMACEUTICALS, INC. (US) | 2008-03-20 | — | — | WO | disclosed |
| US-7312227-B2 | Compositions useful as inhibitors of JAK and other protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-12-25 | — | — | US | disclosed |
| US-7312227-B2 | Compositions useful as inhibitors of JAK and other protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-12-25 | — | — | US | disclosed |
| US-7312227-B2 | Compositions useful as inhibitors of JAK and other protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-12-25 | — | — | US | disclosed |
| EP-1562911-A1 | COMPOSITIONS USEFUL AS INHIBITORS OF JAK AND OTHER PROTEIN KINASES | Vertex Pharmaceuticals Incorporated (US) | 2005-08-17 | — | — | EP | disclosed |
| US-20040147507-A1 | Compositions useful as inhibitors of JAK and other protein kinases | VERTEX PHARMACEUTICALS INCORPORATED | 2004-07-29 | — | — | US | disclosed |
| WO-2004041789-A1 | COMPOSITIONS USEFUL AS INHIBITORS OF JAK AND OTHER PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2004-05-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040147507-A1 | Compositions useful as inhibitors of JAK and other protein kinases | JAK1, JAK2, JAK3 | CDK1 113/4885MTOR 129/4885CDK2 250/4885 |
| US-20080125417-A1 | CERTAIN PYRIMIDINES, METHOD OF MAKING, AND METHOD OF USE THEREOF | BTK, SYK, TK1 | CDK1 221/4885MTOR 1798/4885CDK2 107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.